ICAD: Kapitalisasi marang pendapatan iCAD Inc.
iCAD, Inc. (ICAD) automates the primary analysis of images using AI, outpacing radiologists in both speed and accuracy. The historical P/S dynamics visualize the market valuation of these technologies, where 5.50 shows the current value of the metric. Business efficiency is based on the integration of software into radiology, while patents and FDA approval create significant barriers to entry for new players.
Rincian analitis perusahaan iCAD, Inc. (ICAD)
- rega lan prakiraan konsensus rega:
- informasi kapitalisasi pasar:
- indikator nilai buku ekuitas:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi iCAD, Inc.|ICAD - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal icadmed.com|ICAD - Utang perusahaan|Rasio utang marang nilai buku iCAD Corp|ICAD - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan iCAD|Koefisien jangkoan perantara icadmed.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ICAD - Bathi resik|Prakiraan bathi perusahaan iCAD, Inc.|ICAD - Pangali P/E|Prakiraan rega marang bathi icadmed.com|ICAD - Pangali PEG|Pangali EV/EBITDA iCAD Corp|ICAD - Bathi operasional EBITDA|Bathi saben saham sajrone 12 wulan pungkasan iCAD|ICAD - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan icadmed.com|ICAD - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep iCAD, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:iCAD Inc. (ICAD)
The P/S multiple relates the market capitalization of iCAD, Inc. (ICAD) to its annual revenue, allowing for a business valuation relative to actual sales volume without the influence of net income. By analyzing the current P/S level, an investor can determine the degree of asset overvaluation, given that high R&D costs and the slow adoption of AI diagnostics in medicine create risks for future margins.
Perusahaan pesaing
Koefisien rega marang pendapatan beigene.com|Multiplikator P/S HALO (Halozyme)|RVMD - Kapitalisasi marang pendapatan|Ascentage - Multiplikator P/S|CGON - Multiplikator P/S|URGN: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BCAX|Kapitalisasi marang pendapatan PSNL|ERAS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DCTH|Koefisien rega marang pendapatan Y-mAbs Corp|Rasio rega marang pendapatan Aura Biosciences, Inc. AURA|CADL: Rasio kapitalisasi marang pendapatan|Accuray - Multiplikator P/S|SELLAS Life Sciences (SLS) - Kapitalisasi marang pendapatan|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|CTOR - Koefisien rega marang pendapatan|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|protaratx.com (TARA) - Koefisien rega marang pendapatan|Multiplikator P/S FATE|Kapitalisasi marang pendapatan aadibio.com WHWK|Multiplikator P/S TCRX (TScan Therapeutics, Inc.)|Multiplikator P/S Champions Oncology Inc CSBR|XBiotech USA - Multiplikator P/S|CVM (CEL-SCI Corporation) - Rasio kapitalisasi marang pendapatan|OSTX: Multiplikator P/S|Kapitalisasi marang pendapatan radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator P/S|Multiplikator P/S Adlai Nortye Limited|Rasio rega marang pendapatan Veru Inc. (VERU)|tempesttx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XLO (Xilio Therapeutics)|RENB - Kapitalisasi marang pendapatan|Mural Bio - Multiplikator P/S|Rega marang dodolan Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Rasio rega marang pendapatan|CytoMed Therapeutics Limited - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CRIS|APLM: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S THAR|Kapitalisasi marang pendapatan advanbiomed.com ADVB|Genprex, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S Calidi Biotherapeutics Inc. CLDI|SBFM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan XBIO (Xenetic Biosciences)|SLRX: Multiplikator P/S|Rega marang dodolan Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - Multiplikator P/S|beigene.com (BGNE) - Koefisien rega marang pendapatan|Multiplikator P/S CKPT|Kapitalisasi marang pendapatan elevationoncology.com ELEV|Multiplikator P/S IKNA (Ikena Oncology)|Multiplikator P/S Notable Labs Corp NTBL|Viracta - Multiplikator P/S|MOR (morphosys.com) - Rasio kapitalisasi marang pendapatan|NAYA (NAYA Biosciences Inc.) - Kapitalisasi marang pendapatan|Ascentage Pharma Group International - Rasio kapitalisasi pasar marang pendapatan
